SynthesisEuropean journal of heart failure2022
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
Synthesis in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05950867 (Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause), which is not on this map. Cited by 89 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause: a Prospective Monocentric Study (CAP-TTR)
Who cites it
89 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis.ESC heart failure · 2026Pooled it
- Machine learning-based methods in diagnosing cardiac amyloidosis: a meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Prognostic value of CMR parametric mapping in cardiac amyloidosis: an updated systematic review and meta-analysis.Open heart · 2025Pooled it
- Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis.European journal of clinical investigation · 2025Pooled it
- Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review.Orphanet journal of rare diseases · 2025Pooled it
- Mexican position paper for the diagnosis and treatment of cardiac amyloidosis.Archivos de cardiologia de Mexico · 2024Guideline
- Diagnosis of heart failure with preserved ejection fraction: a systematic narrative review of the evidence.Heart failure reviews · 2024Pooled it
- Bidirectional impact between cardiovascular comorbidities and heart failure: an updated position paper from the Italian society of cardiology (SIC) working group on heart failure.Heart failure reviews · 2026Article
- Cardiac Amyloidosis: Pathogenesis, Diagnosis, and Treatment.Deutsches Arzteblatt international · 2026Review
- Transthyretin Cardiac Amyloidosis in Women: Underdiagnosis, Sex-Specific Phenotypic Expression and Therapeutic Response.Journal of clinical medicine · 2026Review
- A No-Code, Guideline-Based Custom GPT Outperforms Cardiologists in Response Quality for Cardiac Amyloidosis.JACC. Advances · 2026Article
- AI-assisted diagnosis of cardiac amyloidosis using electrocardiograms and echocardiography: a multicenter retrospective study in China.BMC medicine · 2026Article
- Position Statement on Multimodal Cardiac Imaging in Patients with Systemic Diseases - 2026.Arquivos brasileiros de cardiologia · 2026Article
- Don't raise your white flag facing a sea of red ones: when cardiac amyloidosis mimics hypertrophic cardiomyopathy.ESC heart failure · 2026Article
- Uncovering the gene variants in a global cohort of patients with unexplained increased left ventricular wall thickness using next-generation sequencing.BMC cardiovascular disorders · 2026Article
- Machine-learning approach on echocardiography to improve the detection of transthyretin amyloid cardiomyopathy: GRAAL algorithm.European heart journal. Digital health · 2026Article
- Hereditary Transthyretin Amyloidosis in Austria: Clinical, Genetic, and Demographic Insights from a Nationwide Cohort.Journal of clinical medicine · 2026Article
- Structural heart disease screening using artificial intelligence-enabled electrocardiogram and novice handheld cardiac ultrasound: a cost analysis.European heart journal open · 2026Article
- Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA.Current cardiology reports · 2026Review
- Aortic Valve Stenosis: Progress from Diagnosis to Treatment.Journal of clinical medicine · 2026Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAn algorithm for non-invasive diagnosis of amyloid transthyretin cardiac amyloidosis (ATTR-CA) and novel disease-modifying therapies have prompted an active search for CA. We examined the prevalence of CA in different settings based on literature data. METHODS AND
resultsWe performed a systematic search for screening studies on CA, focusing on the prevalence, sex and age distribution in different clinical settings. The prevalence of CA in different settings was as follows: bone scintigraphy for non-cardiac reasons (n = 5 studies), 1% (95% confidence interval [CI] 0%-1%); heart failure with preserved ejection fraction (n = 6), 12% (95% CI 6%-20%); heart failure with reduced or mildly reduced ejection fraction (n = 2), 10% (95% CI 6%-15%); conduction disorders warranting pacemaker implantation (n = 1), 2% (95% CI 0%-4%); surgery for carpal tunnel syndrome (n = 3), 7% (95% CI 5%-10%); hypertrophic cardiomyopathy phenotype (n = 2), 7% (95% CI 5%-9%); severe aortic stenosis (n = 7), 8% (95% CI 5%-13%); autopsy series of 'unselected' elderly individuals (n = 4), 21% (95% CI 7%-39%). The average age of CA patients in the different settings ranged from 74 to 90 years, and the percentage of men from 50% to 100%. Many patients had ATTR-CA, but the average percentage of patients with amyloid light-chain (AL) CA was up to 18%.
conclusionsSearching for CA in specific settings allows to identify a relatively high number of cases who may be eligible for treatment if the diagnosis is unequivocal. ATTR-CA accounts for many cases of CA across the different settings, but AL-CA is not infrequent. Median age at diagnosis falls in the eighth or ninth decades, and many patients diagnosed with CA are women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.